Definitions of Measures of Effect Duration for Psoriasis Treatments

Krueger G.G. , Feldman S.R. , Camisa C. , Duvic M. , Elder J.T. , Gottlieb A.B. . Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43: 281–285.

Koo J. , Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999; 41: 51–9.

Carlin C.S. , Feldman S.R. , Krueger G.G. PASI 50: a clinically significant endpoint in the assessment of psoriasis (manuscript in preparation).

Al Suwaidan S.N. , Feldman S.R. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 2000; 42: 796–802.